The identification of acquired CALR mutations in patients with essential thrombocythaemia (ET) or myelofibrosis (MF) has meant that disease-initiating mutations can now be detected in about 90% of all patients with a myeloproliferative neoplasm (MPN). Here, we show that only those CALR mutations that cause a +1 frameshift, thereby altering the carboxy-terminus of calreticulin, promote cytokine independence in vitro; in-frame deletions were not functional, and are unlikely to be the pathogenetic mutation underlying some MPN cases. Expression of the thrombopoietin receptor, MPL, was also necessary for factor-independence. Although the CALR mutations are considered to occur only in JAK2 V617F-negative cases and in a heterozygous state, progenitor genotyping revealed that this is not always true. Notably, CALR mutation-positive MPNs can be polyclonal: in one case, two distinct CALR mutation-positive subpopulations could be identified; in another, separate populations of JAK2 V617F-positive and CALR-mutated cells were present. Mitotic recombination involving chromosome 19 in a third instance resulted in the emergence of a CALR mutation-homozygous subclone. Collectively, our studies demonstrate that occasional patients with CALR mutation-positive ET or MF carry other MPN-initiating genetic mutations (including JAK2 V617F), acquire "secondary mutations" before or after the CALR mutation, or evolve over time to being CALR mutation-homozygous.
Following the discovery in late 2013 of acquired CALR mutations in patients diagnosed with a BCR/ABL1-negative myeloproliferative neoplasm (MPN) (Klampfl et al, 2013; Nangalia et al, 2013) , disease-initiating mutations can now be identified in approximately 90% of all cases. A number of studies indicate that these mutations occur in 20-35% of patients with essential thrombocythaemia (ET) or with primary or post-thrombocythaemic myelofibrosis (MF), but are rare or non-existent in either polycythaemia vera (PV) or post-polycythaemic MF (Klampfl et al, 2013; Nangalia et al, 2013; Andrikovics et al, 2014; Rotunno et al, 2014; Tefferi et al, 2014a,b; Wu et al, 2014) . CALR mutations in patients with these disorders are considered to occur only in JAK2 V617F-negative blood cells, and then in a heterozygous state. On occasion, CALR mutations may also occur in patients with chronic neutrophilic leukaemia, a rare BCR/ABL1-negative MPN, or a myelodysplastic syndrome (MDS)/MPN overlap syndrome, such as refractory anaemia with ringed sideroblasts and thrombocytosis (RARS-T) or atypical chronic myeloid leukaemia (Klampfl et al, 2013; Lasho et al, 2014; Tefferi et al, 2014c) .
Thirty-six different CALR MPN-associated variants were originally described; all caused a +1 frameshift that results in the replacement of the calreticulin carboxy-terminal domain with a novel sequence of up to 55 amino acids in length (Klampfl et al, 2013) . The "type-1" (52-base deletion) and "type-2" (5-base insertion) variants account for about 80% of CALR-mutated alleles; it has been proposed that the remainder can be considered to be "type 1-like" or "type 2-like" (Tefferi et al, 2014a) . Compared to ET patients with a JAK2 V617F mutation, CALR-mutated ET patients have higher platelet numbers, lower leucocyte counts and lower haemoglobin levels; they also present at a younger age, but have a lower risk of thrombosis (Rotunno et al, 2014; Rumi et al, 2014; Tefferi et al, 2014c) . CALR-mutated patients with MF present with higher haemoglobin levels, higher platelet counts and lower leucocyte counts than their JAK2 V617F-positive counterparts, and those with a type-2 CALR mutation have an overall reduced survival compared to those with a type-1 CALR mutation (Tefferi et al, 2014d) .
Two useful murine models of the CALR-mutated MPNs were recently described . In this study, recipients of murine bone marrow cells expressing a mutated CALR protein developed an isolated thrombocytosis due to megakaryocyte hyperplasia; the phenotype associated with a type-1 CALR variant was significantly more pronounced than that mediated by a type-2 variant. This was partly due to the differential effects of the two variants on haematopoietic stem and progenitor populations; although both increased the numbers of megakaryocyte precursors in murine recipients, only the type-1 CALR variant caused an expansion of the stem cell compartment. A combination of increased stem and megakaryocytic precursor involvement resulted in an overall significant increase in megakaryocyte and platelet production associated with the type-1 variant relative to that associated with the type-2 variant. Accordingly, the majority of recipients of bone marrow expressing the type-1, but not the type-2, variant developed MF 6 months after transplantation; this was characterized by declining red blood cell and platelet counts in the peripheral blood, decreased bone marrow cellularity and splenomegaly. Marked osteosclerosis and increased reticulin fibre deposition were also observed within the marrow of these mice.
In agreement with these in vivo findings, in vitro studies have revealed that mutant (type-1 or type-2) CALR confers growth factor independence only when expressed together with MPL, the receptor for thrombopoietin (THPO) (Araki et al, 2016; Chachoua et al, 2016) ; co-expression with the receptors for erythropoietin (EPO) or granulocyte-colony stimulating factor did not result in cytokine-independent proliferation. MPL and mutant CALR expression in the absence of THPO led to activation of the JAK/STAT pathway, with increased levels of phospho-STAT1, phospho-STAT3 and phospho-STAT5. Co-immunoprecipitation studies suggest that MPL, JAK2 and mutant (but not wildtype) CALR form a complex in vitro, resulting in increased levels of phospho-JAK2 (Araki et al, 2016; Chachoua et al, 2016; Elf et al, 2016) . The mutation-specific nature of this interaction is due to the positive electrostatic charge of the novel carboxy-terminal CALR sequence introduced by a +1 frameshift mutation; this interferes with the ability of the CALR P-domain to block interactions between the N-terminal domain and MPL (Araki et al, 2016; Elf et al, 2016) . Binding of mutant CALR to MPL does not cause receptor dimerization, but may structurally alter MPL in a fashion similar to that induced by its engagement by THPO. This then results in relative repositioning of the JAK2 monomers tethered to the intracellular domain, facilitating autophosphorylation in trans, and activation of the JAK/STAT pathway.
To better understand the biology of the CALR-mutated MPNs, we evaluated the mutation status of the JAK2, MPL and CALR genes in a cohort of 179 patients. Several of the mutation-positive cases were of particular interest, with one showing that, as with JAK2 or MPL mutation-positive MPNs (Scott et al, 2006; Percy et al, 2007; Beer et al, 2008) , mitotic recombination can lead to the emergence of a mutation-homozygous sub-clone. In addition, progenitor genotyping revealed that CALR mutation-positive MPNs may be biclonal: separate populations of CALR-mutated and JAK2-mutated cells were identified in one instance; in another, discrete cell sub-populations were identified that were positive for either a type-1 or a type-2 CALR mutation. In another example, a patient with a CALR mutation tested positive for a DNMT3A mutation (Ley et al, 2010) , with the genotyping of individual progenitors demonstrating that acquisition of the DNMT3A mutation preceded that of the CALR mutation. Collectively, these studies show that, contrary to conventional wisdom, occasional patients are CALR mutation-homozygous or carry other MPN-associated mutations that may be acquired before or after the CALR mutation.
Materials and methods

Sample genotyping
The University of Queensland Research Ethics Committee (#2013001580) approved this study. Haematopoietic colony assays were performed essentially as previously described (Baxter et al, 2005) in either the presence or absence of 2 IU/ml recombinant EPO (Peprotech, Rocky Hill, NJ, USA). DNA samples derived from purified granulocytes, buccal cells or haematopoietic colonies were genotyped by direct sequencing, with the following primers used for amplification and/or sequencing (as underlined): JAK2 exon 12: CTCCTC TTTGGAGCAATTCA and GAGAACTTGGGAGTTGCGATA; JAK2 V617F: GGGTTTCCTCAGAACGTTGA and TCATTG CTTTCCTTTTTCACAA; MPL (exon 10): TGGGCCG AAGTCTGACCCTTT and CAGAGCGAACCAAGAATGCC TGT; CALR (exon 9): ACAACTTCCTCATCACCAACG and GGCCTCAGTCCAGCCCTG; DNMT3A (exon 23): TCCT GCTGTGTGGTTAGACG and ATGATGTCCAACCCTT TTCG.
Cytokine-independence assays
32D cl3 cells were maintained in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal calf serum (FCS) and 10% WEHI 3B-conditioned media as a source of murine interleukin-3 (IL3). BaF3 cells were maintained in RPMI medium supplemented with 10% FCS and 10% WEHI 3B-conditioned media. These cells were first incubated with MSCV-MPL-iresGFP, MSCV-EPOR-iresGFP, or MSCV-CSF3R-iresGFP retroviral particles generated after introducing packaging plasmids and retroviral vectors in 293T cells by CaPO 4 precipitation, and harvesting culture supernatants 2 days later. The resulting transduced green fluorescent protein (GFP)-positive cell populations were purified 3 days later by fluorescence-activated cell sorting (FACS). Various mutations were introduced by site-directed mutagenesis into the wildtype CALR cDNA (IMAGE clone 3898550; ThermoFisher Scientific, Scoresby, Victoria, Australia) using the following primers: type 1 deletion: TCATCATCCTCCTT GTCCTCTGCTCCTCGTCC and GGACGAGGAGCAGAGG ACAAGGAGGATGATGA; type 2 insertion: AGGAGGCA GAGGACAATTGTCGGAGGATGATGAGG and CCTCATC ATCCTCCGACAATTGTCCTCTGCCTCCT; internal deletion: CAAACAGGACGAGGAGGATGAGGAGGACAAGGA and TC CTTGTCCTCCTCATCCTCCTCGTCCTGTTTG; L367X: CG AGGAGCAGAGGCTTTAGGAGGAGGAAGA and TCTT CCTCCTCCTAAAGCCTCTGCTCCTCG; and K385X: TTG TCCTCATCATCCTACTTGTCCTCTGCCTCC and GGAGG CAGAGGACAAGTAGGATGATGAGGACAA. To express the in-frame E380Rfs*38 mutant arising from a 1137-1138insAG and a 1227-1231del change within the same CALR allele (Allen et al, 2014) , sequential frameshift mutations were introduced via the primers AAACGCAAAGAGGA GAGGAGGAGGCAGAGGAC and GTCCTCTGCCTCCT CCTCTCCTCTTTGCGTTT, and GGAAGATGAGGAGGAA GATGTGCCAGGCCAAG and CTTGGCCTGGCACATCTT CCTCCTCATCTTCC, respectively. Mutated CALR cDNAs were individually cloned into MSCV-PGKpuro (Clontech, Mountain View, CA, USA), recombinant retroviral particles were produced as described above, and used to transduce 32D/MPL, 32D/G-CSFR, 32D/EPOR, BaF3/MPL, BaF3/G-CSFR or BaF3/EpoR cells. Doubly transduced cells were then expanded by selection in puromycin for 10 days. IL3-independence assays were performed as described (Scott et al, 2007a) , with the viable cell counts from three independent experiments combined for subsequent statistical analysis.
JAK2 inhibition assays
To test the sensitivity to pharmacological inhibitors of the JAK/STAT pathway, 10 6 32D/MPL cells expressing a type-1 CALR mutant, a type-2 CALR mutant or the in-frame E380Rfs*38 CALR mutant were cultured in 10 ml media lacking exogenous IL3, and in the presence or absence of various concentrations of ruxolitinib (Jomar Life Research, Scoresby, Victoria, Australia). JAK2 V617F-positive HEL and JAK2-wildtype K562 cell-lines served as positive and negative controls. Viable cell numbers were assessed 96 h later and the normalized viability calculated by dividing the cell number at each inhibitor concentration by the number with vehicle (dimethylsulphoxide) alone. Data from three independent experiments were combined for analysis.
Analysis of loss-of-heterozygosity on chromosome 19
The analysis of chromosome 19-based single nucleotide polymorphisms (SNPs) was performed on DNA from single burst-forming units-erythroid (BFU-e) by direct sequencing with the primer pairs listed in Table SI .
Statistical analyses
An unpaired Student's t-test was used to compare the numbers of viable 32D/MPL cells in IL3 withdrawal assays; a chi-square test was used to compare the frequency of DNMT3A-and CALR-mutated BFU-e in Patient E's blood samples over time. A P value of less than 0Á05 was considered statistically significant.
Results
Analysis of a 179-member cohort for the presence of disease-associated mutations
In order to assess the mutation profile of our MPN cohort, the genotypes of JAK2 exons 12 and 14, MPL exon 10 and CALR exon 9 in purified granulocytes and buccal cells were determined in 71 cases of ET, 72 cases of PV and 36 cases of MF. In agreement with our earlier finding (Scott et al, 2007b) , every patient diagnosed with PV was positive for a JAK2 V617F (n = 68) or a JAK2 exon 12 mutation (n = 4); none of these individuals was positive for an additional MPL or CALR mutation. In contrast, 39 ET patients were JAK2 V617F-positive, two were MPL W515L-positive, and 23 were CALR-mutated (11 type-1, nine type-2, and one individual with a CALR type-1-like variant that was only recently identified (Riera et al, 2016) ). Mutant CALR allele burdens did not change significantly over time in the three cases of ET for which matched diagnostic and follow-up samples were available ( Figure S1 ). In addition, 17 patients with MF were JAK2 V617F-positive, one was MPL W515L-positive and one MPL W515K-positive, and 12 were CALR-mutated (six type-1; three type-2). Overall, these mutational frequencies accord well with the findings of others (Klampfl et al, 2013; Nangalia et al, 2013; Andrikovics et al, 2014; Rotunno et al, 2014; Wu et al, 2014) . Given the small number of patients in our cohort, and the wealth of published data on the phenotypic consequences of an acquired CALR mutation, we did not correlate genotypes with haematological phenotype.
CALR mutation-associated cytokine independence requires the novel COOH-terminal sequence
Excluded from this summary is one primary MF patient that lacked JAK2 and MPL mutations (Patient A) and that appeared to have a CALR frameshift mutation, although this was subsequently found to also occur to a similar degree in cells from a buccal swab ( Figure S2A ). As the sequence
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ª 2017 John Wiley & Sons Ltd variation started at nucleotide 1093 of the CALR open reading frame, we thought that this might be a novel variant that was also present within the germline. To determine the exact identity of the mutated allele, CALR exon 9 PCR products were cloned into a plasmid vector and used to transform competent bacterial cells. DNA sequencing revealed that a 96-base deletion was present in 53% of the colonies analysed, which was consistent with a heterozygous CALR mutation present in the vast majority of Patient A's granulocytes. However, in contrast to almost all MPN-associated CALR mutations reported thus far, this deletion did not perturb the open reading frame, so that the resulting polypeptide lacked residues 365-396 of wildtype protein but still included the endoplasmic reticulum retention signal (KDEL) present at the CALR carboxy-terminus ( Figure S2A ). The activity of this internal deletion, and of several other CALR variants, was assessed in vitro using cytokine withdrawal assays. In the initial set of experiments, 32D cl3 murine myeloblast cells were firstly transduced with a retrovirus encoding a type-I cytokine receptor: MPL, the receptor for thrombopoietin; EPOR, the receptor for erythropoietin; or G-CSFR (also termed CSF3R), the receptor for granulocytecolony stimulating factor (G-CSF). These transduced cell populations were subsequently transduced by a retrovirus encoding wildtype or mutated CALR. As reported recently (Araki et al, 2016; Chachoua et al, 2016; Elf et al, 2016; Marty et al, 2016) , cytokine-independent proliferation occurred in cells expressing MPL, but not in cells expressing either EPOR or G-CSFR (Fig 1A) . Similar proliferation profiles were obtained in parallel experiments that instead used BaF3 cells (data not shown). Cytokine independence was observed for the two clinically relevant variants tested: the type-1 and type-2 mutants. Notably, there was a significant increase in the mean viable cell count associated with the type-1 variant at day 6 (12Á697 9 10 6 cells compared to 4Á941 9 10 6 cells for the type-2 variant; P < 0Á001). However, cells expressing a CALR construct in which a termination codon had been introduced to replace residues L367 or K385 (the respective sites of the type-1 and type-2 frameshift mutations) did not proliferate in the absence of exogenous IL3, suggesting that loss of the carboxy terminal sequence, including the KDEL endoplasmic reticulum retention signal, is not sufficient to change the activity of calreticulin in the blood cells of MPN patients, and that the addition of a novel sequence is required. Next, we tested our in-frame internal deletion mutant in 32D cl3 cells expressing MPL, as well as a similar variant in which the patient had two separate mutations on the same CALR allele (1137_1138insAG, and 1227_1231del) (Allen et al, 2014) . The more proximal of these was an insertion of two nucleotides, resulting in a frameshift, whereas the more distal one was a 5-base deletion that restores the original reading frame. The latter alteration replaces the final twenty amino acids of the consensus mutant peptide with the last seven residues of the wildtype protein ( Figure S3 ). This, a derivative that produces a type-2-like CALR mutant polypeptide, and a type-2 CALR mutant polypeptide, were all associated with IL3-independent proliferation in vitro (Fig 1B) . However, 32D/MPL cells expressing the internal deletion mutant detected in Patient A failed to proliferate (Fig 1B) . The observation that this mutant has no demonstrable activity in vitro suggests that, rather than a disease-initiating genetic lesion, the 96-base deletion detected in Patient A is a rare polymorphism.
As patients with CALR-mutated ET and MF respond to treatment with a JAK inhibitor (Guglielmelli et al, 2016) , we also explored the activity of the 1137_1138insAG, 1227_1231del double mutant (Allen et al, 2014) by testing its response, and that of the type-1 and type-2 CALR variants, to the JAK1/2 inhibitor, ruxolitinib (Fig 1C) . In all three instances, ruxolitinib reduced the number of viable 32D/MPL cells, propagated in the absence of exogenous IL3, in a dosedependent manner. This finding suggested that this atypical variant, like the CALR type-1 and -2 variants, inappropriately activates JAK/STAT signalling.
CALR mutation homozygosity can arise through mitotic recombination of chromosome 19
Five of the CALR mutation-positive patients within our cohort were of particular interest. The first (Patient B) was a 57-year-old female diagnosed with ET. Analysis of her CALR gene in granulocytes and buccal cells sampled at diagnosis revealed the presence of an acquired type-2 mutation (Fig 2A) . The granulocyte sequence trace was suggestive of mutation homozygosity occurring in a subset of cells, a phenomenon that has been noted to occur only rarely (Klampfl et al, 2013) . However, as the dideoxy sequencing methodology used is not considered to be quantitative, we genotyped single haematopoietic colonies derived from the patient's peripheral blood (PB) mononuclear cells. The majority of colony-forming units-granulocyte/macrophage (CFU-GM) and BFU-e screened were found to be mutation-homozygous (Fig 2A) , with a genotype profile consistent with the sequential accumulation of mutations within a haematopoietic stem/progenitor cell (HSPC) to produce first a CALR mutation-heterozygous cell and then a CALR mutation-homozygous one.
To identify the mechanism underlying mutation homozygosity in this case, the sequence of regions of chromosome 19 was determined in patient buccal cells, with that of informative SNPs then ascertained in single haematopoietic colonies. The SNPs tested included rs1010222, which is approximately 800 bases proximal to the CALR 5 0 untranslated region, and rs1049481, which lies immediately downstream of the CALR stop codon (Fig 2B) . The patient was found to be homozygous for the G allele of rs1049481, but informative at the rs1010222 locus. Loss-of-heterozygosity was detected specifically in CALR homozygous-mutant BFUe at the rs1010222 locus ( Fig 2B) and in several loci that Fig 1. CALR mutation-associated cytokine independence requires the novel COOH-terminal sequence. (A) Cytokine withdrawal assays were performed in the interleukin-3 (IL3)-dependent 32D cl3 cell-line. These cells had been engineered to express wildtype MPL, wildtype EPOR or wildtype GCSFR, in addition to one of a series of CALR proteins: wildtype (in green), type-1 and type-2 mutants (blue and red, respectively), or two related truncation mutants, L367X and K385X (in teal and orange, respectively). In three independent experiments, 10 5 /ml 32D cells were cultured without IL3 for 6 days, with cell numbers and viability assessed in duplicate on a daily basis. The mean cell count (AEstandard deviation) for each cell-line is shown. (B) Additional cytokine withdrawal assays were performed in 32D cells engineered to express wildtype MPL in addition to one of a series of CALR proteins: wildtype (shown in green), type-2 mutant (red), the internal deletion mutant seen in Patient A (purple), a compound 1138insAG, 1227-1231del mutant (brown) (Allen et al, 2014) , or a related 1138insAG mutant (pink). In three independent experiments, 10 5 /ml 32D cl3 cells were cultured without IL3 for 6 days, with cell numbers and viability assessed in duplicate on a daily basis. The mean cell count (AEstandard deviation) for each cell-line is shown. (C) To test the sensitivity to pharmacological inhibitors of the JAK/STAT pathway, 32D/MPL cells expressing a type-1 CALR mutant (blue), a type-2 CALR mutant (red), or the in-frame E380Rfs*38 CALR mutant (brown) were cultured in the absence of exogenous IL3 for 96 h. Cultures were supplemented with 0Á05, 0Á1, 0Á5, 1Á0 and 10 ruxolitinib (Jomar Life Research, Scoresby, Victoria, Australia). JAK2 V617F-positive HEL (green) and JAK2-wildtype K562 (black) cell-lines served as positive and negative controls, respectively. Viable cell numbers were determined, and the normalized viability calculated by dividing the cell number at each inhibitor concentration by the number with vehicle (dimethylsulphoxide) alone. Data from three independent experiments were combined for analysis.
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altogether span a region of >5 Mb (Table SI) , demonstrating that mutation homozygosity in this instance had arisen via mitotic recombination rather than by acquisition of a second type-2 CALR mutation.
A proportion of CALR mutation-positive cases are bi-clonal Single colony analysis also identified an individual with postthrombocythaemic MF (Patient C) who carried two separate CALR mutations. Although this was not apparent in the granulocyte sequencing trace (Fig 3A) , BFU-e genotyping revealed the presence of a minor type-1 CALR mutation-heterozygous clone in addition to the predominant clone with a heterozygous type-2 CALR mutation (which occurred in 56 of the 82 BFU-e genotyped). The mutually exclusive distribution pattern may indicate the independent acquisition of two CALR mutations by separate HSPCs, although it is also possible that each CALR-mutated sub-clone arose from a single CALR-wildtype HSPC that carried a mutation that predisposed its daughter cells to acquiring an MPN-related mutation. However, the relationship of the affected cells to one another could not be ascertained using X-inactivation analysis (Beer et al, 2009) , as the patient was male.
Similarly, a 54-year-old female with ET (Patient D) was found to have co-incident type-1 CALR and JAK2 V617F mutations (Fig 3B) , a phenomenon that has been noted several times previously. To determine the spatio-temporal relationship of these mutations in Patient D, we genotyped single PB-derived haematopoietic colonies for both mutation types. Discrete sub-populations were detected in both CFU-GM and BFU-e: one was JAK2 V617F-heterozygous, the other was CALR mutation-heterozygous (Fig 3B and data not shown). Colonies that were doubly positive for a JAK2 and CALR mutation were not present. The mutation pattern observed is consistent with a bi-clonal disorder that resulted from the independent acquisition of JAK2 and CALR mutations in separate HSPCs, although the identity of the mutation that had occurred first could not be determined in this instance. Interestingly, each EPO-independent erythroid colony (EEC) that was evaluated was JAK2 V617F-heterozygous, suggesting that a CALR frameshift mutation alone cannot confer EPO-hypersensitivity to developing red blood cells. This possibility is consistent with the paucity of CALR mutations in patients with PV, and our previous observation that EECs rarely occur in patients with JAK2 V617F-negative ET .
Acquisition of a DNMT3A mutation may precede that of a CALR mutation
To further evaluate the clonal architecture within CALR-mutated patients within our cohort, we genotyped PB DNA samples for several of the MPN-associated mutations that target proteins with an epigenetic function, including those in ASXL1, DNMT3A and TET2. Acquired mutations within these genes were mutually exclusive, and more likely to occur in MF than in ET (5 of 12 CALR-mutated cases and 3 of 23 cases, respectively). Where possible, individual haematopoietic colonies from affected individuals were also genotyped; in almost all cases, an ASXL1, DNMT3A or TET2 mutation was detected in a subset of colonies that were CALR mutation-heterozygous (data not shown), indicating that they were acquired subsequent to a CALR frameshift mutation. In contrast, in the single case in which a DNMT3A mutation was found (Patient E, diagnosed with ET), the mutation distribution indicated that the DNMT3A R882H mutation had occurred first: all of the CALR-mutated BFU-e, and most (38 of 44) of the CALR-wildtype BFU-e, in a diagnostic PB sample were mutation-positive (Fig 4A) . However, the acquisition of a DNMT3A mutation in our cohort members did not always precede a JAK2, MPL or (Table SI) was determined using the patient's buccal cells (data not shown). The sequence of rs1010222 (which maps to approximately 800 base pairs proximal to the 5 0 untranslated region of the CALR gene) and other informative loci was then determined in individual BFU-e previously genotyped for the type-2 CALR mutation.
CALR mutation: genotyping of progenitors from two other individuals (one with JAK2 V617F-positive ET, the other with JAK2 V617F-positive post-polycythaemic MF) showed that DNMT3A mutations could occur prior to, or following, the acquisition of a JAK2 mutation (Fig 4B) .
A second analysis of Patient E's BFU-e performed 28 months later did not identify any DNMT3A-wildtype colonies (Fig 4A) , suggesting that this mutation provides affected HSPCs with an in vivo competitive advantage, in agreement with previous studies (Shlush et al, 2014) . Over this period, there was also a moderate increase in the frequency of DNMT3A-mutated and CALR-mutated progenitors, from 28% (15 of 53) at diagnosis to 48% (34 of 72) at follow-up (P = 0Á03), suggesting that the CALR mutation provides an additional proliferative advantage to DNMT3A-mutated cells in vivo.
Discussion
Although our understanding of the biology of CALR mutations is still developing, conventional wisdom has held that these are present only in patients with JAK2 V617F-negative, MPL-wildtype ET or MF, and that they exist in these instances as heterozygous variants. However, using an unbiased genotyping strategy and DNA derived from single cells, we identified rare cases in which neither assertion was valid. Instead, clonal hierarchy in the CALR mutation-positive MPNs is strikingly similar to that noted in JAK2-mutated or MPL-mutated cases. In our cohort, two of the 35 CALR frameshift mutation-positive patients have an oligo-clonal disease: one had separate clones that were positive for either a CALR type-1 or a CALR type-2 mutation (Patient C; Fig 3A) , the other had separate clones that were positive for a JAK2 V617F or a CALR type-2 mutation (Patient D; Fig 3B) . Although several examples of co-existent CALR and MPL mutations have been reported (Shen et al, 2014; Kim et al, 2015; Lin et al, 2015) , none of our cohort members were found to be double-positive.
To our knowledge, the existence of a CALR-mutated patient in which two different and independent CALR mutations are present has not been previously reported. Cases such as this support the possibility that a minority of MPN patients are pre-disposed to acquiring multiple CALR mutations, a phenomenon that has been identified for the JAK2 mutations (Olcaydu et al, 2009; Scott & Rebel, 2012) . Recently, CALR mutations were found to occur more frequently on the T allele of individuals heterozygous for the rs1049481 (G/T) SNP, with an allelic bias of 1Á7 in those with a type-1 mutation, and 2Á1 in those with a type-2 mutation (Harutyunyan et al, 2015) . Patient C was informative at this locus; however, BFU-e positive for a type-2 mutation had the T allele mutated, and the minority with a type-1 mutation had the G allele mutated (data not shown). In this instance, the appearance of separate CALR mutations does not appear to be linked to the CALR haplotype. MPN patients with a type-2 CALR mutation may carry coincident JAK2 or type-1 CALR mutations. (A) Sequence analysis of peripheral blood DNA revealed an acquired type-2 CALR mutation, whereas genotyping of 84 BFU-e identified a minor population with a heterozygous type-1 CALR mutation (present in approximately 8% of erythroid progenitors). The grey arrow indicates the pattern of clonal evolution from one or more wildtype HSPCs to ones that are positive for distinct CALR mutations. (B) One patient with ET was identified that had co-incident type-1 CALR and JAK2 V617F mutations. Two discrete populations were noted: a JAK2 V617F-heterozygous one (35 of 65 BFU-e), and one heterozygous for a CALR mutation (25 of 65 BFU-e). These sub-populations were also present within the CFU-GM population (data not shown). The grey arrow indicates the pattern of clonal evolution from one or more wildtype HSPCs to ones that are positive for a single CALR or single JAK2 mutation. All erythropoietin-independent erythroid colonies (EECs) tested were JAK2 V617F-heterozygous, suggesting that the presence of a CALR mutation is not sufficient to confer cytokine-independence to developing erythroid cells.
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In contrast, co-existent JAK2 V617F and CALR frameshift mutations have been noted in individual cases of ET or MF (Lundberg et al, 2014; McGaffin et al, 2014; Tefferi et al, 2014c) , but not studied further. In one other study, 4Á2% of all ET patients were reported to be double-positive (Min-Gu et al, 2016) , although the low (<1%) JAK2 V617F allele burden in each of these cases raises the possibility that many may be false-positives. In Patient D, haematopoietic colony genotyping revealed the co-existence of two discrete cell populations: one JAK2 V617F-positive, and one CALR type-2 mutation-positive (Fig 3B) . These sub-populations were of approximately equal size, in agreement with the sequence traces obtained from granulocyte DNA that suggested mutation heterozygosity at each locus. The absence of EECs positive for a CALR frameshift mutation in this patient suggests that the expression of mutant calreticulin does not confer EPO-hypersensitivity to developing red blood cells, which accords well with the in vitro studies described here ( Fig 1A) and elsewhere (Araki et al, 2016; Chachoua et al, 2016; Elf et al, 2016) that demonstrate that cytokine-independent proliferation of cells carrying type-1 or type-2 CALR mutations occurs only in the presence of MPL, a receptor that is not expressed by maturing red blood cells.
Clonal evolution from a CALR-heterozygous disorder to a CALR-homozygous one, reminiscent of that patients with JAK2 V617F-positive PV (Scott et al, 2006) , was detected in one patient with ET (Fig 2) . Mutant CALR allele frequencies that are suggestive of homozygosity are rare in MPN patients; only three examples of apparent homozygosity were detected in 286 CALR-mutated cases (from a cohort of 1215 patients with ET or MF) (Klampfl et al, 2013) . Most mutation-homozygous individuals have primary or post-thrombocythaemic MF (Rumi et al, 2014; Theocharides et al, 2016) ; the case reported here (Patient B), and one other (Klampfl et al, 2013) , were diagnosed with ET. Mutation homozygosity in Patient B was not the result of an independent mutation event within her remaining wildtype CALR allele, but rather by mitotic recombination that produced a region of uniparental disomy (UPD) within chromosome 19 that included the CALR locus (Fig 2B) . This event would have preceded diagnosis, as most of the clonogenic progenitors assessed at that time were already mutation-homozygous (Fig 2A) . The clinical consequences of CALR mutation homozygosity remain unclear, although a subgroup of MF patients (6 of 81), most of whom were CALR mutationhomozygous, were shown to have acquired myeloperoxidase (MPO) deficiency (Theocharides et al, 2016) . However, this disorder was absent in 94 patients with ET, so it is unlikely to be caused by CALR mutation-homozygous alone.
In another MPN patient, we identified a CALR variant that resulted in a calreticulin molecule in which 32 amino acid residues within the C-terminal were absent. This variant did not facilitate IL3-independent proliferation in vitro, in Acquisition of a DNMT3A mutation may precede that of a CALR mutation. (A) Patient E, with CALR-mutated ET, also had an acquired DNMT3A mutation (R882H). Genotype analysis of 59 BFU-e colonies cultured from peripheral blood taken at diagnosis and of 72 BFU-e colonies from blood taken 28 months later ("follow-up") suggests that the CALR mutation was acquired in haematopoietic stem/progenitor cell (HSPC) that already carried a DNMT3A mutation. The grey arrow indicates the pattern of clonal evolution from a wildtype HSPC to one that is positive for CALR and DNMT3A mutations. (B) Patients F and G also had acquired DNMT3A mutations. The grey arrows indicates the deduced pattern of clonal evolution in each case: Patient F, who had JAK2 V617F-positive ET, acquired the DNMT3A R882C mutation first, whereas Patient G, who had post-polycythaemic MF, acquired the JAK2 V617F mutation first. direct contrast to several other (frameshift) mutants tested in parallel, suggesting that the factor-independent proliferation of MPL-expressing blood cells required the presence of a novel carboxy-terminal domain (Fig 1B) . This is not the only recent report of germline mutations in the CALR exon 9 being detected. In an analysis of 2000 blood samples submitted to a Canadian hospital for mutation testing, 12 had germline variations characterized by an absence of nucleotides from exon 9 (Szuber et al, 2016) . Interestingly, these resembled the variant we report here, in that the deletions did not alter the reading frame (that is, they occurred in multiples of three nucleotides). Other single examples of inframe deletions in patients with an MPN have been reported in the literature (as summarized in Figure S2B ), where they were often characterized as being a CALR mutation. Furthermore, two established SNPs, rs550353351 and rs754300025, cause the respective absence of three or five residues from the calreticulin protein. The former SNP has an apparent allele frequency in the African cohort of the 1000 Genome Consortium (http://browser.1000genomes.org/index.html) of 1%, and 0Á1% in the Mixed American cohort; information on the allele frequency of the other is not available. All of these variants occur in the carboxy-terminal region of the calreticulin protein encoded by exon 9, essentially spanning the region in which the frameshifts associated with an MPN occur ( Figure S3 ). Their occurrence, and the existence of somatically acquired mutations in individuals that develop an MPN, may signify that this area of the human genome is inherently unstable. This instability might be due to the complexity of the local DNA sequence, which contains trinucleotide repeats as well as longer repeat elements.
The identification of allelic variants in the population that involve in-frame deletions has important implications for the screening of MPN patients: some may receive a diagnosis of a CALR-mutated MPN when there is no functionally relevant mutation present. This appears to be the case for several patients reported in the literature (Kim et al, 2015; Park et al, 2015b; Xu et al, 2015; Zamora et al, 2015; Murugesan et al, 2016; Rashid et al, 2016) . Current screening methods include DNA sequencing, PCR product size analysis and high-resolution melting-curve (HRM) analysis, with the latter two having a significantly lower monetary cost than the former (Park et al, 2015a) . However, these two methods would also be unable to distinguish between in-frame and frameshift variants that differ by only one base pair, and may result in a false-positive test result. As germline in-frame deletions should have an allelic frequency of 50%, any CALR exon 9 mutation detected by product size or HRM analysis that has an allelic frequency of close to 50% should be characterized further by DNA sequencing.
Whilst some patients with PV and a CALR mutation-positive genotype may be explained by the recording of a constitutional in-frame deletion as a mutation, other rare cases do exist (Lundberg et al, 2014; Tefferi et al, 2014c) . In these instances, the patients are positive for both a JAK2 V617F mutation and a CALR mutation. Although we did not detect any such case, colony genotyping of two other cohort members may provide insights into the pathogenesis of JAK2-mutated, CALR-mutated PV. It is possible that an individual similar to Patient B, with bi-clonal ET consisting of mutually-exclusive JAK2-mutated and CALR-mutated clones, could undergo polycythaemic transformation associated with the development of a dominant JAK2 V617F-homozygous sub-clone derived from a JAK2 V617F-heterozygous HSPC. A similar mutation accrual pattern was detected in another patient, whose clinical presentation over time and colony data were suggestive of transformation from JAK2 V617F-positive ET to JAK2 V617F-positive PV, with further clonal evolution involving the emergence of a subset of cells carrying an N542-E543del (JAK2 exon 12) mutation (data not shown). Although colony analysis of JAK2-and CALR-mutated patients would be required to verify this scenario, the granulocyte sequence of one of the afore-mentioned doublepositive patients is consistent of JAK2 V617F-homozygosity (Tefferi et al, 2014c) .
Clonal haematopoiesis of indeterminate potential (CHIP) is a phenomenon in which acquired mutations that had previously been associated only with the presence of a blood cancer can be detected in haematologically normal individuals (Genovese et al, 2014; Jaiswal et al, 2014; McKerrell et al, 2015) . Amongst the most commonly mutated genes in these studies were TET2, ASXL1, DNMT3A, JAK2 and SRSF2, with DNMT3A mutations occurring in almost half of all mutation-positive cases. The frequency of these mutations increased dramatically with age, such that about 10% of those aged over 70 years, and 20% of those aged over 90 years, were affected. The presence of a mutation was not associated with any alteration in haemoglobin levels, platelet numbers, or total or differential white cell counts, suggesting that affected individuals did not have an undiagnosed blood cancer, although they were found to collectively have an increased risk of subsequently developing a haematological malignancy compared with age-matched persons without mutations (Genovese et al, 2014; Jaiswal et al, 2014; McKerrell et al, 2015) . In light of these findings, it is interesting that Patient E had a mutation pattern in his progenitor population that was consistent with the sequential acquisition of a DNMT3A R882H mutation, and then a CALR type-1 mutation. Given that the patient was 89 years old when diagnosed with ET, it is plausible that he had previously had CHIP. However, rather than subsequently developing MDS or an acute myeloid leukaemia, this individual developed a CALR-mutated MPN. Unfortunately, blood samples taken prior to diagnosis were not available to test this possibility.
In summary, our studies collectively demonstrate that, while the mechanism that causes myeloproliferation in patients with an acquired CALR mutation is distinct, the pattern of clonal evolution and the accrual of mutations over time is strikingly similar to that previously reported for MPN patients with acquired JAK2 or MPL mutations.
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